H.C. Wainwright reiterates UroGen Pharma stock rating on FDA filing acceptance

Markets Investing.com By Investing.com 20 Oct 2026 11:40 1 min read
H.C. Wainwright reiterates UroGen Pharma stock rating on FDA filing acceptance

Covered in this story

What has happened since

Price move measured from the close nearest publication to the latest quote.

Call it yourself

No calls on $URGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on Urogen Pharma LTD →
Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.